Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
4DMedical Ltd ( (AU:4DX) ) has issued an announcement.
4DMedical Limited has secured a $10 million strategic investment from Pro Medicus, a leader in medical imaging software. This investment will help 4DMedical accelerate its commercial pipeline and advance its CT:VQ™ product towards regulatory clearance in the U.S. The investment is structured as a hybrid debt and equity loan, aligning the interests of both companies’ shareholders. This strategic move is expected to strengthen 4DMedical’s market position and enhance its growth prospects, particularly with the anticipated FDA clearance of CT:VQ™ and the company’s expanding partnerships and operational growth.
The most recent analyst rating on (AU:4DX) stock is a Buy with a A$0.70 price target. To see the full list of analyst forecasts on 4DMedical Ltd stock, see the AU:4DX Stock Forecast page.
More about 4DMedical Ltd
4DMedical Limited is a global medical technology company specializing in respiratory care through advanced imaging and AI-powered solutions. The company is known for its patented XV Technology®, which provides dynamic quantification of lung ventilation, and its FDA-cleared XV Lung Ventilation Analysis Software. 4DMedical’s solutions integrate into existing hospital infrastructure via a SaaS model, enhancing diagnostic capabilities for respiratory diseases.
Average Trading Volume: 800,559
Technical Sentiment Signal: Sell
Current Market Cap: A$109.4M
For an in-depth examination of 4DX stock, go to TipRanks’ Overview page.